Provectus Biopharmaceuticals, Inc. · OTC:PVCT
Provectus Biopharmaceuticals — Investor Presentation (2026)
19 slides from Provectus Biopharmaceuticals's investor presentation, Jan 19, 2026
Slide 1: Igniting the Embers of Hope: Small Molecule Immunotherapies
IGNITING THE EMBERS OF HOPE SMALL MOLECULE IMMUNOTHERAPIES ROSE BENGAL MEDICAL SCIENCE INVESTOR PRESENTATION / 2026 Copyright © 2026 Provectus Biopharmaceuticals, Inc. OTCQB: PVCT
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS The information in this presentation may include “forward-looking Due to the risks, uncertainties, and assumptions inherent in statements” within the meaning of U.S. federal securities legislation forward-looking statements, readers should not place undue and relating to t
Slide 3: The Rose Bengal Sodium (RBS) Molecule
THE ROSE BENGAL SODIUM (RBS) MOLECULE OTCQB: PVCT 3
Slide 4: Executive Summary
EXECUTIVE SUMMARY Provectus Biopharmaceuticals (OTCQB: PVCT) is a clinical-stage biotechnology company with a bioactive small molecule platform of immunotherapy drug candidates and formulations. Socioeconomic Benefits of Better Healthcare 1 Better, accessible, and affordable healthcare can boost liv
Slide 5: Executive Summary (continued)
EXECUTIVE SUMMARY (continued) RBS Medical Science Injectable Solid Tumor Oncology 2 Innovation, versatility, and consistency drive clinical and 3 Pursuing clinical, regulatory, and commercial milestone financial value compared to standard of care medicines. RBS achievements for lead intratumoral can
Slide 6: Our Unyielding Resolve
OUR UNYIELDING RESOLVE VISION Transforming the way the healthcare industry treats disease MISSION To innovate safe, effective, accessible, and affordable immunotherapy medicines, while revolutionizing the healthcare industry as we know it Igniting the Embers of Hope OTCQB: PVCT 6
Slide 7: The Science Behind RBS
THE SCIENCE BEHIND RBS RBS MEDICAL SCIENCE: Platform Value Proposition Global accessibility via affordability Safety Autolysis of Injected Tumor Tissue DAMP & Antigens Release, DC Recruitment, Antigen Uptake Precise, personalized & Broad- potentially spectrum Intralesional Injection permanent activi
Slide 8: Go To Market Strategy
GO TO MARKET STRATEGY Provectus: The only source of effectively pure, Our RBS manufacturing processes employ QbD principles, meet cGMP regulations, and follow ICH guidelines. regulatorily viable, commercially differentiated RBS API Provectus employs process controls to eliminate the formation of his
Slide 9: Immunotherapy Treatment for Cancer
IMMUNOTHERAPY TREATMENT FOR CANCER 10 MILLION (est.) People Die Annually from Cancer1 Provectus is a clinical-stage biotechnology company developing immunotherapy treatments for cancer and many other diseases based on a class of halogenated xanthene molecules. Our flagship molecule is Rose Bengal So
Slide 10: Injectable Solid Tumor Oncology: Penile SCC
INJECTABLE SOLID TUMOR ONCOLOGY Co-Lead Indication • Pre-operative penile squamous cell carcinoma (SCC) Penile SCC • Monotherapy intratumoral PV-10 • SOC is penectomy 6-to-9-Patient, Single-Site, Phase 1 Trial • Maximizes PV-10’s intrinsic advantages • Rapid local response • Tissue preservation pre-
Slide 11: Injectable Solid Tumor Oncology: mPDAC
INJECTABLE SOLID TUMOR ONCOLOGY Co-Lead Indication • FOLFIRNOX-refractory pancreatic ductal adenocarcinoma metastatic to the liver mPDAC • Intratumoral PV-10 + systemic gemcitabine+nab-paclitaxel (GEM-PAC) • 2nd-line: Versus historical GEM-PAC; est. 7 months median OS1 18-Patient, Single-Site, Dose
Slide 12: AI-Assisted Cancer Mechanism Analysis of RBS
AI-ASSISTED CANCER MECHANISM ANALYSIS OF RBS Hypothesis • RBS acts through a multiplicity of anti-cancer mechanisms. Methodology • Conducted a systematic, GPT-4-assisted, review and analysis of 457 PubMed-indexed articles1 mentioning “rose bengal” and “cancer” from 1958 to 2026. • Traced mechanistic
Slide 13: RBS Medical Science Platform
RBS MEDICAL SCIENCE PLATFORM Disease Administration Notes Oncology itu. PV-10: Stage III and IV melanoma; Cancers of the liver; Co-lead indications: penile SCC & mPDAC CLINICAL STAGE Ophthalmology top. PV-305: Infectious keratitis1 (spun-out from Provectus as VisiRose, Inc.) Dermatology top. PH-10:
Slide 14: The Future of Eye Care: Introducing VisiRose
INTRODUCING VISIROSE Vision is humanity’s most treasured sense. Yet for countless people worldwide, the scourge of eye THE FUTURE OF infection and disease has stolen this precious faculty of sight, cloaking them in shadows, discomfort, and often EYE CARE perpetual darkness. Rose Bengal & VisiRose is
Slide 15: Leadership Team
LEADERSHIP TEAM Ed Pershing, CPA Dominic Rodrigues John Lacey, III, M.D. CEO & Chairman of the Board President & Vice Chairman of the Board Director • Former CEO and co-founder of Pershing Yoakley & • Management consulting and corporate development in • Former Chief Medical Officer and Senior Vice A
Slide 16: Our Competitive Advantage
OUR COMPETITIVE ADVANTAGE Open-Source Scientific Research Network Supporting Proprietary Drug Development We employ open-source collaboration for basic, applied, and translational medical research, identifying and working with expert physician-researchers and scientists in different disease areas wh
Slide 17: Capital Markets Snapshot
CAPITAL MARKETS SNAPSHOT Mailing Address Provectus Biopharmaceuticals, Inc. 800 S. Gay St., Suite 1610 Knoxville, TN 37929 USA Ticker PVCT +1 (866) 594-5999 / Fax: +1 (866) 998-0005 Exchange OTCQB Investor Relations investorrelations@pvct.com Sector Biotechnology +1 (866) 594-5999 x1 Media Relations
Slide 18: Why Invest in Provectus
WHY INVEST IN PROVECTUS Committed to developing Corporate principles Clinical trials Open-source network of Highly experienced & safe, effective, accessible of cure, accessibility, demonstrating physician-researchers, passionate management and affordable accountability, viability of lead cancer scie
Slide 19: OTCQB: PVCT
Copyright © 2026 Provectus Biopharmaceuticals, Inc. OTCQB: PVCT www.ProvectusBio.com info@provectus.com OTCQB: PVCT 19
Provectus Biopharmaceuticals — Investor Presentation (2026) on 6ix